Over-ambitious ThromboGenics 'explores options' after poor US Jetrea launch
This article was originally published in Scrip
ThromboGenics of Belgium has admitted that commercializing its eye drug Jetrea (ocriplasmin) alone in the US has proved more difficult that anticipated. It has decided to explore "strategic options" in a bid to boost disappointing US sales.
You may also be interested in...
ProQR spinout Amylon gets started by licensing four central nervous system disorder candidates from its parent, while start-up Eyevance gets US rights to Nicox’s Zerviate.
The UK's main reimbursement bodies made a series of decisions this week that were broadly favorable and largely focused on oncology medicines.
While troubled Valeant was divesting iNova to private equity investors, Novartis announced a pair of oncology-focused deals, out-licensing a brain cancer drug to Midatech and partnering with IBM Watson Health to optimize breast cancer treatment.